Immunonutrition vs EPA-DHA Enriched Nutritional Support in Patients With Cancer Undergoing Surgery

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-85
SponsorMaimónides Biomedical Research Institute of Córdoba

About this trial

To compare clinical and molecular effects of nutritional support (immunonutrition or EPA-DHA enriched oral nutritional supplements) in patients with cancer undergoing surgery.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with cancer undergoing surgery (primary tumor location; gastrointestinal tract, ovarian, peritoneal carcinomatosis)

Disqualifiers

End-stage liver disease

End-stage kidney disease

Trial population

Patients with cancer undergoing surgery (primary tumor location; gastrointestinal tract, ovarian, peritoneal carcinomatosis

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Immunonutrition

    Dietary supplement

    Patients will receive nutritional advice and 2 oral nutritional supplements with arginine, fatty acids and nucleotides

  • EPA-DHA

    Dietary supplement

    Patients will receive nutritional advice and 2 oral nutritional supplements enriched with EPA and DHA

Treatment groups

80 Participants
are divided into 1 treatment group
Group A: Patients with cancer undergoing surgery (primary tumor location: gastrointestinal tract, ovary)2 interventions

Trial outcomes

Primary outcomes

1

Body composition changes

changes in fat mass, fat-free mass, lean mass and phase angle

Time frame
1-3 months

Secondary outcomes

1

Cytokines changes

Changes in circulating cytokines (IL6, IL8, MIP10)

Time frame
1-3 months
2

Metabolites changes

Changes in circulating metabolites including lipids and muscle-related metabolites

Time frame
1-3 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.